Clinical Trial Search

Primary: The Incidence of Durable Hematopoietic Engraftment for T-cell Depleted Transplants Fractionated by the CliniMACS System Administered After Each of the Four Disease…

Primary: Overall Response Rate — 6; 30; 17; 0 Participants

Primary: Efficacy as Assessed by 2-year PSA Progression-free Survival Rate — 17 Participants

Primary: Main: Absolute Change From Baseline in Hepatic Fat Fraction Assessed by MRI-PDFF at Week 12. — -12.32; -13.44; -14.14; -0.29 Absolute percentage of hepatic fat

Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs) — 0; 1; 1; 0 Participants

Primary: Percentage of Participants Experiencing Clinically Relevant Hypotension — 15.4; 16.7 Percent of participants

Primary: Number of Patients With Dose Limiting Toxicities — 0; 0 Participants

Primary: Change From Baseline in Average Pain Intensity as Measured by the NRS — -1.98; -1.56 score on a scale

Primary: Phase 2: Number of Participants With Objective Response Rate (ORR) Using RECIST v1.1 — 2; 9; 24; 14 Participants — p=0.0158

Primary: The Progression Free Survival (PFS) — 1.8 months

Primary: 6-month Response Rate (Complete Response, Partial Response, and Stable Disease) — 9; 15; 4 Participants

Primary: Phase 1: Percentage of Participants With a Solicited Injection-site Adverse Event (AE) — 10.0; 23.3; 20.0; 73.3 Percentage of participants

Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -8.6; -8.0; -9.5; -10.6 score on a scale — p=>0.05

Primary: Change From Baseline in the Montreal Cognitive Assessment (MoCA) Total Score at Week 12 of Treatment — 13.9; 13.8; -0.6; -0.4 score on a scale — p=0.6909

Primary: Latency to Initiate Ad-lib Smoking Session — 31.55; 30.31 minutes